@article{8ec2e150813745578362a9df4a1e14af,
title = "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension",
abstract = "We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.",
keywords = "cardiac fibrosis, galectin-3, heart failure",
author = "Lau, {Emily S.} and Elizabeth Liu and Paniagua, {Samantha M.} and Sarma, {Amy A.} and Giovanna Zampierollo and Bego{\~n}a L{\'o}pez and Javier D{\'i}ez and Wang, {Thomas J.} and Ho, {Jennifer E.}",
note = "Funding Information: This work was supported by National Institutes of Health Grant Nos. NIH-5T32HL094301-07 (to Dr. Lau), R01-HL134893 (to Dr. Ho), R01-HL140224 (to Dr. Ho), and K24-HL153669 (to Dr. Ho) and a Gilead Sciences Research Scholar Award (to Dr. Ho). Dr. Ho has received research grants from Gilead Sciences and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Research supplies (modified citrus pectin and placebo) were donated for use in this study by EcoNugenics, Inc. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = jan,
doi = "10.1016/j.jacbts.2020.10.006",
language = "English (US)",
volume = "6",
pages = "12--21",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "1",
}